Evaluating Atorvastatin With Omega-3 Fatty Acids in Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
NCT ID: NCT00141232
Last Updated: 2021-02-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
810 participants
INTERVENTIONAL
2004-11-30
2006-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
What proportion of people with Type 2 Diabetes are likely to be treated satisfactorily with a fixed dose of a statin that lowers blood cholesterol levels to help reduce the risk of heart disease? To what extent do omega-3 fatty acids lower blood triglyceride levels when given with or without a statin? Are there simple techniques that can help people to take their tablets on a regular basis?
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events
NCT00327418
Amlodipine/Atorvastatin Combination to Reduce the Health Risk of High Blood Pressure and High Cholesterol Levels
NCT00143234
A Study Of The Efficacy Of Atorvastatin For Lowering Cholesterol In High-Risk Patients With High Cholesterol
NCT00644670
Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)
NCT00442845
Atorvastatin For The Reduction Of Ventricular Arrhythmias
NCT00457340
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atorvastatin and Omega-3 fatty acids
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Are not known to have had a cardiovascular event
Exclusion Criteria
* Have triglycerides \> or = 8.0 mmol/L
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Churchill Hospital
OTHER
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Irvine, Ayrshire, United Kingdom
Pfizer Investigational Site
Farnworth, Bolton, United Kingdom
Pfizer Investigational Site
Thornhill, Cardiff, United Kingdom
Pfizer Investigational Site
Fowey, Cornwall, United Kingdom
Pfizer Investigational Site
Launceston, Cornwall, United Kingdom
Pfizer Investigational Site
Penzance, Cornwall, United Kingdom
Pfizer Investigational Site
Penzance, Cornwall, United Kingdom
Pfizer Investigational Site
Saltash, Cornwall, United Kingdom
Pfizer Investigational Site
St Austell, Cornwall, United Kingdom
Pfizer Investigational Site
Darlington, County Durham, United Kingdom
Pfizer Investigational Site
Newton Aycliffe, County Durham, United Kingdom
Pfizer Investigational Site
Three Bridges, Crawley, United Kingdom
Pfizer Investigational Site
Plymouth, Devon, United Kingdom
Pfizer Investigational Site
Plymouth, Devon, United Kingdom
Pfizer Investigational Site
Bexhill-on-Sea, East Sussex, United Kingdom
Pfizer Investigational Site
Bexhill-on-Sea, East Sussex, United Kingdom
Pfizer Investigational Site
Bath, England, United Kingdom
Pfizer Investigational Site
Dronfield, Sheffield, England, United Kingdom
Pfizer Investigational Site
Surrey, England, United Kingdom
Pfizer Investigational Site
Halstead, Essex, United Kingdom
Pfizer Investigational Site
Stonehouse, Gloucestershire, United Kingdom
Pfizer Investigational Site
Southampton, Hampshire, United Kingdom
Pfizer Investigational Site
Hildenborough, Kent, United Kingdom
Pfizer Investigational Site
Thorneton-Clevely, Lancashire, United Kingdom
Pfizer Investigational Site
Balham, London, United Kingdom
Pfizer Investigational Site
Fulham, London, United Kingdom
Pfizer Investigational Site
Tooting, London, United Kingdom
Pfizer Investigational Site
Hayes, Middlesex, United Kingdom
Pfizer Investigational Site
Wellingborough, Northamptonshire, United Kingdom
Pfizer Investigational Site
Cookstown, Northern Ireland, United Kingdom
Pfizer Investigational Site
Frome, Somerset, United Kingdom
Pfizer Investigational Site
Fetcham, Surrey, United Kingdom
Pfizer Investigational Site
Woking, Surrey, United Kingdom
Pfizer Investigational Site
Crawley, West Sussex, United Kingdom
Pfizer Investigational Site
Leeds, West Yorkshire, United Kingdom
Pfizer Investigational Site
Bradford-on-Avon, Wiltshire, United Kingdom
Pfizer Investigational Site
Melksham, Wiltshire, United Kingdom
Pfizer Investigational Site
Swindon, Wiltshire, United Kingdom
Pfizer Investigational Site
Trowbridge, Wiltshire, United Kingdom
Pfizer Investigational Site
Warminster, Wiltshire, United Kingdom
Pfizer Investigational Site
Sheffield, Yorkshire, United Kingdom
Pfizer Investigational Site
Bath, , United Kingdom
Pfizer Investigational Site
Bath, , United Kingdom
Pfizer Investigational Site
Belfast, , United Kingdom
Pfizer Investigational Site
Birmingham, , United Kingdom
Pfizer Investigational Site
Bucks, , United Kingdom
Pfizer Investigational Site
Chesterfield, , United Kingdom
Pfizer Investigational Site
Chippenham, Wiltshire, , United Kingdom
Pfizer Investigational Site
Cornwall, , United Kingdom
Pfizer Investigational Site
County Antrim, Northern Ireland, , United Kingdom
Pfizer Investigational Site
Darlington, , United Kingdom
Pfizer Investigational Site
Dundee, , United Kingdom
Pfizer Investigational Site
Dundee, , United Kingdom
Pfizer Investigational Site
East Sussex, , United Kingdom
Pfizer Investigational Site
Isle of Wight, , United Kingdom
Pfizer Investigational Site
Isle of Wight, , United Kingdom
Pfizer Investigational Site
London, , United Kingdom
Pfizer Investigational Site
London, , United Kingdom
Pfizer Investigational Site
Westbury, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A2581114
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.